The historical rank and industry rank for Novelix Pharmaceuticals's Net Margin % or its related term are showing as below:
BOM:536565'
s Net Margin % Range Over the Past 10 Years
Min: -185.05 Med: -2.02 Max: 1.93
Current: 1.93
BOM:536565's Net Margin % is ranked better than 56.41% of 117
companies
in the Medical Distribution industry
Industry Median: 1.47
vs BOM:536565: 1.93
Novelix Pharmaceuticals (BOM:536565) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Novelix Pharmaceuticals Net Margin % Related Terms
Novelix Pharmaceuticals Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:536565 vs MCK, CAH, COR: Net Margin % Comparison
For the Medical Distribution subindustry, Novelix Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novelix Pharmaceuticals Net Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Novelix Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where Novelix Pharmaceuticals's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novelix Pharmaceuticals (BOM:536565) has a Net Margin % of 3.62% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Novelix Pharmaceuticals and its competitors. According to the industry distribution chart, Novelix Pharmaceuticals ranks #51 out of 117 companies in the Medical Distribution industry, placing it in the top 43.6%.
Is Novelix Pharmaceuticals' Net Margin % too high?
Novelix Pharmaceuticals' current Net Margin % is 3.62%. The Medical Distribution industry median Net Margin % is 1.47. Novelix Pharmaceuticals' value of 3.62% is 146.3% above this industry median. Based on the distribution chart, Novelix Pharmaceuticals ranks #51 out of 117 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Novelix Pharmaceuticals has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Novelix Pharmaceuticals' Net Margin % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Novelix Pharmaceuticals ranks #51 out of 117 companies for Net Margin %. This puts Novelix Pharmaceuticals in the upper half of its industry. The industry median Net Margin % is 1.47. Novelix Pharmaceuticals' value of 3.62% is 146.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Distribution company?
The median Net Margin % among Medical Distribution companies is 1.47, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novelix Pharmaceuticals's current Net Margin % of 3.62% is 146.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Novelix Pharmaceuticals and its competitors. For the Medical Distribution industry, the median Net Margin % is 1.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novelix Pharmaceuticals's current Net Margin % is 3.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novelix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Novelix Pharmaceuticals (BOM:536565) is currently considered Possible Value Trap. The stock's GF Value™ is ₹144.17, compared to a current price of ₹77.97 — trading 45.9% below its estimated fair value. The current Net Margin % is 3.62% and 146.3% above the Medical Distribution industry median of 1.47. Novelix Pharmaceuticals' overall GF Score™ is 68/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Novelix Pharmaceuticals (BOM:536565), the current Net Margin % is 3.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novelix Pharmaceuticals (BOM:536565) Overvalued in 2026?
Based on GuruFocus' analysis, Novelix Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹77.97 is trading 45.9% below its estimated GF Value™ of ₹144.17.
GuruFocus considers Novelix Pharmaceuticals to be Possible Value Trap.
Key valuation signals for BOM:536565:
Net Margin %: 3.62%
GF Value™: ₹144.17 vs. price of ₹77.97 (45.9% below fair value)
Industry Position: 146.3% above the Medical Distribution median (#51 of 117)
No single metric tells the full story. See the BOM:536565 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novelix Pharmaceuticals Ltd is into the business of Trading of Pharmaceuticals and related products and is into the business of trading of shares and securities. The company generates majaority of its revenue from the Pharmaceuticals business.
68GF Score
Get the complete analysis for BOM:536565
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:536565 has been successfully added to your 
